Market revenue in 2023 | USD 522.7 million |
Market revenue in 2030 | USD 1,266.6 million |
Growth rate | 13.5% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.19% in 2023. Horizon Databook has segmented the Japan circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the largest manufacturers of generic pharmaceuticals, which represents the world’s eighth largest market in terms of value. The growing geriatric population has increased the medical expenditure in the country. To reduce the healthcare expenses, a cabinet decision was passed in 2015 with an aim to achieve generic drugs share of around 80% by September 2020.
Due to the government efforts for higher use of generics, certain players are expanding their geographical presence and focusing on export of Japanese quality standard products back to their country to gain considerable profit margin.
Moreover, the drug pricing policy of the country is attractive for generic manufacturers, helping them establish their presence in the market. The National Health Insurance System in Japan sets the reimbursement price of generic drugs and biosimilar at 50% or less & 70%, respectively, than the originator drug.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into Japan circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account